Apeiron RIA’s Eli Lilly LLY Stock Holding History

Apeiron RIA’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-221	Closed	-$200K	–	213
2024 Q2	$200K	Buy	+221	New	+$177K	0.06%	203
2022 Q3	–	Sell	-220	Closed	-$713	–	194
2022 Q2	$713	Buy	+220	New	+$66K	0.2%	52

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Apeiron RIA's LLY Position: Q3 2024 in Review

Apeiron RIA sold out of Eli Lilly (LLY) in Q3 2024, closing a stake of 221 shares — an estimated $200K sold.

Apeiron RIA first reported a position in LLY in Q2 2022 and held it in 2 quarters. The position peaked at $200K in Q2 2024. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

Apeiron RIA reported no remaining Eli Lilly position as of Q3 2024 after selling out during the quarter.
Apeiron RIA sold 221 Eli Lilly shares in Q3 2024, an estimated $200K.
Apeiron RIA first reported a position in Eli Lilly in Q2 2022 and held it in 2 quarters.
Apeiron RIA's Eli Lilly position peaked at $200K in Q2 2024.
3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on Apeiron RIA's 13F filing for Q3 2024, filed 14 Nov 2024.